ELSEVIER

Journal of Controlled Release 39 (1996) 411–413

journal of controlled release

Author Index Volume 39 (1996)

Adriaensens, P., see Schacht, E. (39) 327
Allémann, E., see Leroux, J.-C. (39) 339
Allen, T.M., see Zalipsky, S. (39) 153
Amidon, G.L., see Lipka, E. (39) 121
Ammons, D., see Kossovsky, N. (39) 383
Amsden, B.G. and Cheng, Y.-L., Erratum. Enhanced fraction releasable above percolation threshold from monoliths containing osmotic excipients [*Journal of Controlled Release* 31 (1994) 21–32] (39) 109
Anderson, S., see Kossovsky, N. (39) 383
Baban, D.F., see Steyger, P.S. (39) 35
Barnajian, P., see Kossovsky, N. (39) 383
Baudyš, M., Mix, D. and Kim, S.W., Stabilization and intestinal absorption of human calcitonin (39) 145
Bell, C.L. and Peppas, N.A., Modulation of drug permeation through interpolymer complexed hydrogels for drug delivery applications (39) 201
Benet, L.Z., Wu, C.-Y., Hebert, M.F. and Wacher, V.J., Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery (39) 139
Bettini, R., see Colombo, P. (39) 231
Boddé, H.E., see Hoogstraate, A.J. (39) 71
Borchard, G., Lueßen, H.L., De Boer, A.G., Verhoef, J.C., Lehr, C.-M. and Junginger, H.E., The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: Effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro (39) 131
Borchert, J.C.H., see Hennink, W.E. (39) 47
Bowersock, T.L., HogenEsch, H., Suckow, M., Porter, R.E., Jackson, R., Park, H. and Park, K., Oral vaccination with alginate microsphere systems (39) 209
Braslawsky, G.R., see Firestone, R.A. (39) 251
Brazel, C.S. and Peppas, N.A., Pulsatile local delivery of thrombolytic and antithrombotic agents using poly(*N*-isopropylacrylamide-co-methacrylic acid) hydrogels (39) 57
Brereton, M., see Steyger, P.S. (39) 35
Buck, D., see Hollinger, J. (39) 287
Carleer, R., see Schacht, E. (39) 327
Casazza, A.M., see Firestone, R.A. (39) 251
Cheng, Y.-L., see Amsden, B.G. (39) 109
Chien, Y.W., see Lee, C.-H. (39) 93
Chow, K., see Kossovsky, N. (39) 383
Chung, A., see Kossovsky, N. (39) 383
Colombo, P., Bettini, R., Santi, P., De Ascentiis, A. and Peppas, N.A., Analysis of the swelling and release mechanisms from drug delivery systems with emphasis on drug solubility and water transport (39) 231
Crison, J., see Lipka, E. (39) 121
Crowder, J., see Kossovsky, N. (39) 383
Cullander, C., see Hoogstraate, A.J. (39) 71
De Ascentiis, A., see Colombo, P. (39) 231
De Boer, A.G., see Borchard, G. (39) 131
De Jaeghere, F., see Leroux, J.-C. (39) 339
Demeester, J., see Hennink, W.E. (39) 47
De Smedt, S.C., see Hennink, W.E. (39) 47
De Zeeuw, D., see Meijer, D.K.F. (39) 163
Doelker, E., see Leroux, J.-C. (39) 339
Firestone, R.A., Willner, D., Hofstead, S.J., King, H.D., Kaneko, T., Braslawsky, G.R., Greenfield, R.S., Trail, P.A., Lasch, S.J., Henderson, A.J., Casazza, A.M., Hellström, I. and Hellström, K.E., Synthesis and antitumor activity of the immunoconjugate BR96-Dox (39) 251
FitzGerald, D. and Pastan, I., Recombinant immunotoxins for the treatment of cancer (39) 261
Gao, X., see Li, S. (39) 373
Gelan, J., see Schacht, E. (39) 327
Gelman, A., see Kossovsky, N. (39) 383
Gevaert, A., see Schacht, E. (39) 327
Goodwin, C., see Kossovsky, N. (39) 383
Goodwin, D.A., see Renn, O. (39) 239
Görich, S., see Kissel, T. (39) 315
Greenfield, R.S., see Firestone, R.A. (39) 251
Greisler, H.P., Growth factor release from vascular grafts (39) 267
Gurny, R., see Leroux, J.-C. (39) 339
Han, D.K., see Yu, B.G. (39) 65
Han, K., see Yu, B.G. (39) 65
Hansen, C.B., see Zalipsky, S. (39) 153
Hebert, M.F., see Benet, L.Z. (39) 139
Hellström, I., see Firestone, R.A. (39) 251
Hellström, K.E., see Firestone, R.A. (39) 251
Henderson, A.J., see Firestone, R.A. (39) 251
Hennink, W.E., Talsma, H., Borchert, J.C.H., De Smedt, S.C. and Demeester, J., Controlled release of proteins from dextran hydrogels (39) 47
Hnatyszyn, H.J., see Kossovsky, N. (39) 383
Hofland, H., see Li, S. (39) 373
Hofstead, S.J., see Firestone, R.A. (39) 251
HogenEsch, H., see Bowersock, T.L. (39) 209
Hollinger, J., Mayer, M., Buck, D., Zegzula, H., Ron, E., Smith, J., Jin, L. and Wozney, J., Poly(α-hydroxy acid) carrier for

delivering recombinant human bone morphogenetic protein-2 for bone regeneration (39) 287
Hoogstraate, A.J., Cullander, C., Nagelkerke, J.F., Spies, F., Verhoef, J., Schrijvers, A.H.G.J., Junginger, H.E. and Boddé, H.E., A novel in-situ model for continuous observation of transient drug concentration gradients across buccal epithelium at the microscopical level (39) 71
Huang, L., see Li, S. (39) 373
Hubbell, J.A., Hydrogel systems for barriers and local drug delivery in the control of wound healing (39) 305
Jackson, R., see Bowersock, T.L. (39) 209
Jacques, V., see Renn, O. (39) 239
Jeong, S.Y., see Yu, B.G. (39) 65
Jin, L., see Hollinger, J. (39) 287
Junginger, H.E., see Borchard, G. (39) 131
Junginger, H.E., see Hoogstraate, A.J. (39) 71
Kabanov, V.A., Yaroslavov, A.A. and Sukhishvili, S.A., Interaction of polyions with cell-mimetic species: Physico-chemical and biomedical aspects (39) 173
Kaneko, T., see Firestone, R.A. (39) 251
Kataoka, K., see Yokoyama, M. (39) 351
Kato, Y., Seita, T., Kuwabara, T. and Sugiyama, Y., Kinetic analysis of receptor-mediated endocytosis (RME) of proteins and peptides: use of RME as a drug delivery system (39) 191
Kenawy, E.R., see Schacht, E. (39) 327
Kim, S.W., see Baudyš, M. (39) 145
Kim, Y.H., see Yu, B.G. (39) 65
King, H.D., see Firestone, R.A. (39) 251
Kissel, T., Li, Y.X., Volland, C., Görich, S. and Koneberg, R., Parenteral protein delivery systems using biodegradable polyesters of ABA block structure, containing hydrophobic poly(lactide-co-glycolide) A blocks and hydrophilic poly(ethylene oxide) B blocks (39) 315
Koneberg, R., see Kissel, T. (39) 315
Kossovsky, N., Gelman, A., Rajguru, S., Nguyen, R., Sponsler, E., Hnatyszyn, H.J., Chow, K., Chung, A., Torres, M., Zemanovich, J., Crowder, J., Barnajian, P., Ly, K., Philipose, J., Ammons, D., Anderson, S., Goodwin, C., Soliemanzadeh, P., Yao, G. and Wei, K., Control of molecular polymorphisms by a structured carbohydrate/ceramic delivery vehicle – aquasomes (39) 383
Kuwabara, T., see Kato, Y. (39) 191
Kwon, I.C., see Yu, B.G. (39) 65
Lasch, S.J., see Firestone, R.A. (39) 251
Lee, C.-H. and Chien, Y.W., Development and evaluation of a mucoadhesive drug delivery system for dual-controlled delivery of Nonoxynol-9 (39) 93
Lehr, C.-M., see Borchard, G. (39) 131
Leroux, J.-C., Allémann, E., De Jaeghere, F., Doelker, E. and Gurny, R., Biodegradable nanoparticles — From sustained release formulations to improved site specific drug delivery (39) 339
Li, S., Gao, X., Son, K., Sorgi, F., Hofland, H. and Huang, L., DC-Chol lipid system in gene transfer (39) 373
Li, Y.X., see Kissel, T. (39) 315
Lipka, E., Crison, J. and Amidon, G.L., Transmembrane transport of peptide type compounds: Prospects for oral delivery (39) 121
Lopes de Menezes, D.E., see Zalipsky, S. (39) 153
Lueßen, H.L., see Borchard, G. (39) 131
Ly, K., see Kossovsky, N. (39) 383
Mayer, M., see Hollinger, J. (39) 287
Meares, C.F., see Renn, O. (39) 239
Meijer, D.K.F., Molema, G., Moolenaar, F., De Zeeuw, D. and Swart, P.J., (Glyco)-protein drug carriers with an intrinsic therapeutic activity: The concept of dual targeting (39) 163
Mix, D., see Baudyš, M. (39) 145
Molema, G., see Meijer, D.K.F. (39) 163
Molly, K., see Schacht, E. (39) 327
Moolenaar, F., see Meijer, D.K.F. (39) 163
Moran, J.K., see Renn, O. (39) 239
Nagelkerke, J.F., see Hoogstraate, A.J. (39) 71
Nguyen, R., see Kossovsky, N. (39) 383
Nichifor, M., Schacht, E.H. and Seymour, L.W., Macromolecular prodrugs of 5-fluorouracil. 2: Enzymatic degradation (39) 79
Okano, T., see Yokoyama, M. (39) 351
Pardridge, W.M., Physiologic-based strategies for protein drug delivery to the brain (39) 281
Park, H., see Bowersock, T.L. (39) 209
Park, K., see Bowersock, T.L. (39) 209
Park, K.D., see Yu, B.G. (39) 65
Pastan, I., see FitzGerald, D. (39) 261
Peppas, N.A., see Bell, C.L. (39) 201
Peppas, N.A., see Brazel, C.S. (39) 57
Peppas, N.A., see Colombo, P. (39) 231
Philipose, J., see Kossovsky, N. (39) 383
Pitt, C.G. and Schindler, A., Erratum. The kinetics of drug cleavage and release from matrices containing covalent polymer-drug conjugates [*Journal of Controlled Release* 33 (1995) 391–395] (39) 111
Pitt, C.G. and Shah, S.S., Erratum. Manipulation of the rate of hydrolysis of polymer-drug conjugates: the degree of hydration [*Journal of Controlled Release* 33 (1995) 397–403] (39) 113
Pitt, C.G. and Shah, S.S., Manipulation of the rate of hydrolysis of polymer-drug conjugates: The secondary structure of the polymer (39) 221
Porter, R.E., see Bowersock, T.L. (39) 209
Rajguru, S., see Kossovsky, N. (39) 383
Renn, O., Goodwin, D.A., Studer, M., Moran, J.K., Jacques, V. and Meares, C.F., New approaches to delivering metal-labeled antibodies to tumors: Synthesis and characterization of new biotinyl chelate conjugates for pre-targeted diagnosis and therapy (39) 239
Rolland, A.P., see Tomlinson, E. (39) 357
Ron, E., see Hollinger, J. (39) 287
Sakurai, Y., see Yokoyama, M. (39) 351
Sanders, S.W., Transition from temporal to biological control in the clinical development of controlled drug delivery systems (39) 389
Santi, P., see Colombo, P. (39) 231
Schacht, E., Gevaert, A., Kenawy, E.R., Molly, K., Verstraete, W., Adriaensens, P., Carleer, R. and Gelan, J., Polymers for colon specific drug delivery (39) 327
Schacht, E.H., see Nichifor, M. (39) 79
Schindler, A., see Pitt, C.G. (39) 111

Schrijvers, A.H.G.J., see Hoogstraate, A.J. (39) 71
Seita, T., see Kato, Y. (39) 191
Seymour, L.W., see Nichifor, M. (39) 79
Seymour, L.W., see Steyger, P.S. (39) 35
Shah, S.S., see Pitt, C.G. (39) 113
Shah, S.S., see Pitt, C.G. (39) 221
Smith, J., see Hollinger, J. (39) 287
Soliemanzadeh, P., see Kossovsky, N. (39) 383
Son, K., see Li, S. (39) 373
Soon-Shiong, P., Encapsulated islet cell therapy for the treatment of diabetes: Intraperitoneal injection of islets (39) 399
Sorgi, F., see Li, S. (39) 373
Spies, F., see Hoogstraate, A.J. (39) 71
Sponsler, E., see Kossovsky, N. (39) 383
Steyger, P.S., Baban, D.F., Brereton, M., Ulbrich, K. and Seymour, L.W., Intratumoural distribution as a determinant of tumour responsiveness to therapy using polymer-based macromolecular prodrugs (39) 35
Studer, M., see Renn, O. (39) 239
Suckow, M., see Bowersock, T.L. (39) 209
Sugiyama, Y., see Kato, Y. (39) 191
Sukhishvili, S.A., see Kabanov, V.A. (39) 173
Suwa, S., see Yokoyama, M. (39) 351
Swart, P.J., see Meijer, D.K.F. (39) 163
Talsma, H., see Hennink, W.E. (39) 47
Tomlinson, E. and Rolland, A.P., Controllable gene therapy. Pharmaceutics of non-viral gene delivery systems (39) 357
Torres, M., see Kossovsky, N. (39) 383
Trail, P.A., see Firestone, R.A. (39) 251
Ulbrich, K., see Steyger, P.S. (39) 35
Verhoef, J., see Hoogstraate, A.J. (39) 71
Verhoef, J.C., see Borchard, G. (39) 131
Verstraete, W., see Schacht, E. (39) 327
Volland, C., see Kissel, T. (39) 315
Wacher, V.J., see Benet, L.Z. (39) 139
Wei, K., see Kossovsky, N. (39) 383
Willner, D., see Firestone, R.A. (39) 251
Wozney, J., see Hollinger, J. (39) 287
Wu, C.-Y., see Benet, L.Z. (39) 139
Yao, G., see Kossovsky, N. (39) 383
Yaroslavov, A.A., see Kabanov, V.A. (39) 173
Yokoyama, M., Okano, T., Sakurai, Y., Suwa, S. and Kataoka, K., Introduction of cisplatin into polymeric micelle (39) 351
Yu, B.G., Kwon, I.C., Kim, Y.H., Han, D.K., Park, K.D., Han, K. and Jeong, S.Y., Development of a local antibiotic delivery system using fibrin glue (39) 65
Zalipsky, S., Hansen, C.B., Lopes de Menezes, D.E. and Allen, T.M., Long-circulating, polyethylene glycol-grafted immunoliposomes (39) 153
Zegzula, H., see Hollinger, J. (39) 287
Zemanovich, J., see Kossovsky, N. (39) 383

ELSEVIER

Journal of Controlled Release 39 (1996) 415–416

journal of controlled release

Subject Index Volume 39 (1996)

ABA block copolymer, (39) 315
Absorption, (39) 121
Absorption enhancer, (39) 145
Acid-labile hydrazone, (39) 251
Adhesion, (39) 305
Alginate microsphere, (39) 209
5-Aminosalicylic acid, (39) 327
Amphotericin B, (39) 389
Ampicillin sodium, (39) 65
Antibody, (39) 261
Antibody conjugation, (39) 153
Antibody-mediated targeting, (39) 251
Anticancer drug, (39) 351
Anti-HIV agent, (39) 163
Antisense oligonucleotide, (39) 191
Antitumor targeting, (39) 251
Antiviral protein, (39) 163
Asialoglycoprotein, (39) 191
Avidin, (39) 281
Azo polymer, (39) 327
AZT, (39) 163
Bioadhesive strength, (39) 93
Bioavailability, (39) 121
Biotin, (39) 281
Block copolymer, (39) 351
Blood-brain barrier, (39) 281
Bone repair, (39) 287
Bovine serum albumin, (39) 65
Buccal mucosa, (39) 71
Caco-2, (39) 131
Calcium, (39) 93
Cancer, (39) 261
Carbohydrate, (39) 383
Carbomer, (39) 131
Carbopol 934P, (39) 93
Cathepsin, (39) 79
Cell therapy, (39) 399
Ceramic, (39) 383
Chitosan-glutamate, (39) 131
Cisplatin, (39) 351
Coating, (39) 327
Coil expansion, (39) 221
Collagenase, (39) 79
Colonic absorption, (39) 145
Confocal laser scanning microscopy, (39) 71, (39) 131
Conjugate, (39) 221
Controllable gene therapy, (39) 357
Controlled drug delivery, (39) 389
Controlled release, (39) 93, (39) 201
Counter-transport, (39) 139
Cyclosporin, (39) 139
Cytochrome P450 3A, (39) 139
Degradation, (39) 327
Delivery, (39) 121
Denaturation, (39) 383
Dendrimer, (39) 357
Dextran, (39) 47
Diabetes, (39) 399
DNA, (39) 173, (39) 373
DOTA, (39) 239
Doxorubicin, (39) 251
Drug delivery, (39) 35, (39) 71, (39) 267, (39) 351, (39) 383
Drug delivery system, (39) 191
Drug development, (39) 389
Drug targeting, (39) 163, (39) 339
Duodenal absorption, (39) 145
EDTA, (39) 93
Encapsulation, (39) 399
Endocytosis, (39) 251
Endothelial cell, (39) 267
Enhanced permeability and retention effect, (39) 35
Epidermal growth factor, (39) 191
Fibrin glue, (39) 65, (39) 267
Fibrin glue factor, (39) 267
Fibrinolysis, (39) 305
5-Fluorouracil, (39) 79
Front, (39) 231
Fusogenic peptide, (39) 357
Gel layer, (39) 231
Gene delivery system, (39) 357
Gene expression system, (39) 357
Gene therapy, (39) 373
Glycoprotein, (39) 163
Gut metabolism, (39) 139
Heparin, (39) 57, (39) 267
Hepatic targeting, (39) 163
pH sensitivity, (39) 57
Human calcitonin, (39) 145
Human colon, (39) 327
Hydrazone, (39) 251
Hydrogel, (39) 47, (39) 57, (39) 201, (39) 305

Hydrolysis, (39) 221
Immunoliposome, (39) 153
Immunotoxin, (39) 261
Indium-111, (39) 239
Interpolyelectrolyte complex, (39) 173
Intraperitoneal injection, (39) 399
Islet isolation, (39) 399
Kinetics, (39) 221
Latex, (39) 173
Ligand, (39) 261
Liposome, (39) 173, (39) 357, (39) 373
Lysosomal enzyme, (39) 79
Lysosome, (39) 251
Lysozyme, (39) 163
Mesh size, (39) 47
Microsphere, (39) 65, (39) 315
Modulated permeation, (39) 201
Mucoadhesive drug-delivery system, (39) 93
Mucosal immunity, (39) 209
Nanoparticle, (39) 339
Naproxen, (39) 163
Negatively charged albumin, (39) 163
Nonoxynol-9, (39) 93
Non-viral gene therapy, (39) 357
Opsonization, (39) 339
Oral, (39) 121
Oral drug delivery, (39) 145
Oral vaccination, (39) 209
Parenteral delivery, (39) 315
Peptide, (39) 121
P-glycoprotein, (39) 139
Photodymanic therapy, (39) 339
Photopolymerization, (39) 305
Polyacrylate, (39) 221
Poly(α-hydroxy acid), (39) 287
Polyester, (39) 315
Polyethylene glycol, (39) 153
Polyion, (39) 173
Poly(lactic acid), (39) 339
Polymer, (39) 373
Polymer conjugate, (39) 35
Polymeric micelle, (39) 351
Prodrug, (39) 79
Prodrug colon targeting, (39) 327
Protein, (39) 47, (39) 173, (39) 315
Protein/peptide stabilization, (39) 145
Protein release, (39) 47
Purification, (39) 399
Radioimmunoimaging, (39) 239
Radioimmunotherapy, (39) 239
Receptor, (39) 261
Receptor-mediated endocytosis, (39) 191
Recombinant human bone morphogenetic protein-2, (39) 287
Release properties, (39) 315
Renal targeting, (39) 163
Restenosis, (39) 305
Secretory IgA, (39) 209
Solubility, (39) 231
Solute diffusion, (39) 201
Sterically stabilized liposome, (39) 153
Streptokinase, (39) 57
Structure, (39) 221
Surface, (39) 383
Sustained release, (39) 65, (39) 339
Swelling, (39) 231
Targeted drug delivery, (39) 153
Temperature sensitivity, (39) 57
Testosterone, (39) 389
Tetanus toxoid, (39) 315
Theophylline, (39) 389
Toxin, (39) 261
Transepithelial electrical resistance, (39) 131
Transfection, (39) 373
Transplantation, (39) 399
Transport visualization, (39) 71
Vaginal mucosa, (39) 93
Vascular endothelial growth factor (VEGF), (39) 35
Vascular graft, (39) 267
Vascular permeability, (39) 35
Vasoactive intestinal peptide, (39) 281
Water transport, (39) 231
Yttrium-90, (39) 239